Evaluation of safety and efficacy of tranilast in preventing graft-versus-host disease after allogeneic hematopoietic stem cell transplantatio
Not Applicable
Completed
- Conditions
- Paients aged 20 years or greater who undergo allogeneic hematopoietic stem cell transplatation from an unrelated donor
- Registration Number
- JPRN-UMIN000016401
- Lead Sponsor
- Keio University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1) Poorly controlled diabetes even with insulin treatment 2) Poorly controlled hypertension 3) Poorly controlled active infection 4) Not expecting 3 months or longer survival due to refractory disease or infection 5) Requring immediate tapering of immunosuppressant because of high risk of disease replapse 6) Active disease infiltration of central nervous system 7) Active double cancer 8) Pregnant or nursing patients 9) Poorly controlled psychiatric disorder 10) History of hypersensitivity or moderate or greater adverse events due to tranilast, cyclosporine, tacrolimus, and methotrexate.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method on-hematological adverse events within 28 days after transplantation
- Secondary Outcome Measures
Name Time Method